In detail: delcasertib (KAI-9803), a Tat-coupled PKCδ inhibitor which did not show a significant decrease in heart tissue damage from artery-opening being in a Phase II clinical trial, although the drug reduced cardiac damage in a rat model of acute myocardial infarction [111]; and XG-102, a Tat-coupled c-Jun N-terminal kinase (JNK) inhibitor which reduces myocardial ischemia–reperfusion injury and infarction size in rats [112] is currently in an ongoing Phase III clinical trial dealing, surprisingly, with the reduction of intraocular inflammation post-cataract surgery [113]. The gene discussed is TAT; the disease is myocardial infarction.